Search

IntroductionWe aim to examine the population’s perception of physical exercise in patients with cancer.Materials and methodsAn anonymous survey was conducted to reach a sample of Italian adults. The questionnaire investigated sociodemographic factors, physical exercise levels, and perceptions about the importance, benefits, and safety of exercise, the support from oncologists and family/friends, as well as the capability and ease of patients of exercise.ResultsOverall, 838 persons participated in this survey. The majority of respondents agree that exercise is important (60.5%) and beneficial (61.5%) for patients with cancer during anticancer treatments, whereas 40.2% believed in its safety. Forty-two percent and 51.9% of participants expressed a positive opinion regarding the advice of oncologists and the encouragement of family/friends to exercise, respectively. Only 27.2% of respondents feel that patients are capable of exercising, and 9.0% agree that it is easy for them.ConclusionAlthough the population has a favorable perception of the importance and benefits of physical exercise, they do not still believe that patients are capable of performing it. Increasing awareness of the feasibility of a physical exercise intervention in the context of cancer is crucial to supporting patients.

BackgroundThe clinical consequences of pancreatic exocrine insufficiency and its treatment in advanced pancreatic ductal adenocarcinoma (PDAC) are poorly investigated. This retrospective study aims at investigating the pancreatic enzyme replacement therapy (PERT) use and its impact on survival and maldigestion-related symptoms in advanced PDAC patients undergoing chemotherapy.MethodsA retrospective analysis was conducted on advanced PDAC patients, treated with first-line gemcitabine plus nab-paclitaxel at two academic institutions (March 2015-October 2018). Data were correlated with overall survival (OS) using Cox regression model. Kaplan-Meier curves were compared using Log-Rank test.ResultsData from 110 patients were gathered. PERT was administered in 55 patients (50%). No significant differences in baseline characteristics with those who did not receive PERT were found. Median OS for the entire group was 12 months (95% CI 9-15). At multivariate analysis, previous surgical resection of the primary tumor, (HR 2.67, p=0.11), weight gain after 3 months (HR 1.68, p=0.07) and PERT (HR 2.85, p ≤ 0.001) were independent predictors of OS. Patients who received PERT reported an improvement of maldigestion-related symptoms at 3 months more frequently than patients who did not (85.2% vs 14.8%, p ≤ 0.0001).ConclusionPERT is associated with significantly prolonged survival and maldigestion-related symptoms alleviation in advanced PDAC patients.